临床试验证明重组链激酶为一安全、有效的新型溶栓药。
The clinical studies demonstrated that r-SK is a safe and effective new type thrombolytic agent.
重组链激酶的血管开通率高，不良反应主要为轻度过敏反应，低血压及轻度出血。
The patency of infarct-related coronary artery was high. The side effects of r -SK were allergic reaction , hypotension and mild bleeding.
重组链激酶的血管开通率高，不良反应主要为轻度过敏反应，低血压及轻度出血。
The patency of infarct-related coronary artery was high. The side effects of r -SK were allergic reaction , hypotension and mild bleeding.
应用推荐